Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

[1]  王林,et al.  CONSORT , 2011 .

[2]  Michael Goggins,et al.  Detection of Early-Stage Pancreatic Adenocarcinoma , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[3]  K. Jhaveri,et al.  Current and emerging techniques in gastrointestinal imaging. , 2010, Journal of postgraduate medicine.

[4]  A. Larghi,et al.  Pancreatic cancer: diagnosis and endoscopic staging. , 2010, European review for medical and pharmacological sciences.

[5]  David Moher,et al.  CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials , 2010, PLoS medicine.

[6]  N. Brünner,et al.  Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. , 2010, Anticancer research.

[7]  Dante Mantini,et al.  Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. , 2010, Journal of proteomics.

[8]  B. Mroczko,et al.  Clinical Significance of the Measurements of Serum Matrix Metalloproteinase-9 and Its Inhibitor (Tissue Inhibitor of Metalloproteinase-1) in Patients With Pancreatic Cancer: Metalloproteinase-9 as an Independent Prognostic Factor , 2009, Pancreas.

[9]  Christof Schütte,et al.  Serum Peptidome Profiling Revealed Platelet Factor 4 as a Potential Discriminating Peptide Associated with Pancreatic Cancer , 2009, Clinical Cancer Research.

[10]  Wei-Chih Liao,et al.  Serum Heat Shock Protein 27 Is Increased in Chronic Pancreatitis and Pancreatic Carcinoma , 2009, Pancreas.

[11]  J. Disario,et al.  Improved Diagnosis of Pancreatic Adenocarcinoma Using Haptoglobin and Serum Amyloid A in a Panel Screen , 2009, World Journal of Surgery.

[12]  H. Brenner,et al.  Up‐to‐date cancer survival: Period analysis and beyond , 2009, International journal of cancer.

[13]  Nils Brünner,et al.  Banking of Biological Fluids for Studies of Disease-associated Protein Biomarkers* , 2008, Molecular & Cellular Proteomics.

[14]  H. Nielsen,et al.  Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. , 2008, The International journal of biological markers.

[15]  Richard J A Goodwin,et al.  Time‐dependent evolution of tissue markers by MALDI‐MS imaging , 2008, Proteomics.

[16]  Taiping Zhang,et al.  [Present status of and prospects for basic research on pancreatic cancer]. , 2008, Zhonghua yi xue za zhi.

[17]  M. Grossbard,et al.  Metastatic pancreatic cancer 2008: is the glass less empty? , 2008, The oncologist.

[18]  Douglas B. Evans,et al.  Tumor‐Node‐Metastasis Staging of Pancreatic Adenocarcinoma , 2008, CA: a cancer journal for clinicians.

[19]  Yupei Zhao,et al.  Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. , 2007, Hepatobiliary & pancreatic diseases international : HBPD INT.

[20]  Lennart Martens,et al.  The minimum information about a proteomics experiment (MIAPE) , 2007, Nature Biotechnology.

[21]  J. Neoptolemos,et al.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms , 2007, Gut.

[22]  Eithne Costello,et al.  Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.

[23]  Catrin Tudur Smith,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Michelle A. Anderson,et al.  CEACAM1, a Novel Serum Biomarker for Pancreatic Cancer , 2007, Pancreas.

[25]  H. Friess,et al.  Protein profiling of microdissected pancreas carcinoma and identification of HSP27 as a potential serum marker. , 2007, Clinical chemistry.

[26]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  Daniel Hartmann,et al.  Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling , 2007, Pancreas.

[28]  N. Duraker,et al.  CEA, CA 19‐9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice , 2007, Journal of surgical oncology.

[29]  A. Benson Adjuvant therapy for pancreatic cancer: one small step forward. , 2007, JAMA.

[30]  K. Zinkiewicz,et al.  Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. , 2006, Archives of surgery.

[31]  S. Köklü,et al.  Significance of Serum Receptor-Binding Cancer Antigen (RCAS1) in Pancreatic Cancer and Benign Pancreatobiliary Diseases , 2006, Pancreatology.

[32]  X. Yang,et al.  Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. , 2006, Chinese journal of digestive diseases.

[33]  D. Chan,et al.  Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9 , 2006, Clinical Cancer Research.

[34]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[35]  L. Traverso,et al.  Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by Computed Tomography , 2005, Surgical Endoscopy And Other Interventional Techniques.

[36]  D. Wagner,et al.  Plasma storage at −80 °C does not protect matrix metalloproteinase-9 from degradation , 2005 .

[37]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[38]  H. Tao,et al.  Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. , 2004, Hepatobiliary & pancreatic diseases international : HBPD INT.

[39]  L. Gullo,et al.  Tumor M2-Pyruvate Kinase, a New Metabolic Marker for Pancreatic Cancer , 2004, Digestive Diseases and Sciences.

[40]  Jun Wu,et al.  Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. , 2004, World journal of gastroenterology.

[41]  K. Kinzler,et al.  Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers , 2004, Clinical Cancer Research.

[42]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. The Standards for Reporting of Diagnostic Accuracy Group. , 2003, Croatian medical journal.

[43]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. , 2003, Radiology.

[44]  H. Nielsen,et al.  Evaluation of Sample Handling in Relation to Levels of Tissue Inhibitor of Metalloproteinases-1 Measured in Blood by Immunoassay , 2003, The International journal of biological markers.

[45]  R. Hruban,et al.  Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  C. Gatsonis,et al.  Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative , 2003, Clinical chemistry and laboratory medicine.

[47]  J. Neoptolemos,et al.  Prediction of resectability of pancreatic malignancy by computed tomography , 2003, The British journal of surgery.

[48]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[49]  M Blettner,et al.  Measurement error correction using validation data: a review of methods and their applicability in case-control studies , 2000, Statistical methods in medical research.

[50]  J. Rhodes,et al.  Prospective study of CAM 17·1/WGA mucin assay for serological diagnosis of pancreatic cancer , 1997, The Lancet.

[51]  S. Gansauge,et al.  CAM 17.1--a new diagnostic marker in pancreatic cancer. , 1996, British Journal of Cancer.

[52]  C. Haglund,et al.  CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. , 1994, British Journal of Cancer.

[53]  K. Partanen,et al.  A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score. , 1994, British Journal of Cancer.

[54]  G. Banfi,et al.  Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. , 1993, Clinical chemistry.

[55]  C. Lightdale,et al.  Localization of pancreatic endocrine tumors by endoscopic ultrasonography. , 1992, The New England journal of medicine.

[56]  Yusuke Nakamura,et al.  Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma , 2009, Journal of Gastroenterology.

[57]  M. Mori,et al.  Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era? , 2009, Journal of the American College of Surgeons.

[58]  B. Mroczko,et al.  Serum levels of granulocyte colony-stimulating factor (G-CSF) and macrophage colony-stimulating factor (M-CSF) in pancreatic cancer patients , 2007, Clinical chemistry and laboratory medicine.

[59]  D. Wagner,et al.  Plasma storage at -80 degrees C does not protect matrix metalloproteinase-9 from degradation. , 2005, Analytical biochemistry.